CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.958
2.44%
Market Trading Hours* (UTC) Opens on Wednesday at 07:00

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.006
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022099 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022099%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000123 %
Charges from full value of position ($-0.02)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000123%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange Netherlands
Commission on trade 0%

*Information provided by Capital.com

Pharming Group NV ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.982
Open* 0.964
1-Year Change* -5.12%
Day's Range* 0.948 - 0.974
52 wk Range 0.89-1.37
Average Volume (10 days) 11.53M
Average Volume (3 months) 119.94M
Market Cap 746.71M
P/E Ratio -100.00K
Shares Outstanding 669.41M
Revenue 201.14M
EPS -0.03
Dividend (Yield %) N/A
Beta 0.73
Next Earnings Date Mar 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 0.958 -0.008 -0.83% 0.966 0.975 0.948
Apr 15, 2024 0.982 -0.016 -1.60% 0.998 1.008 0.978
Apr 12, 2024 1.007 0.010 1.00% 0.997 1.023 0.997
Apr 11, 2024 0.994 -0.001 -0.10% 0.995 1.004 0.985
Apr 10, 2024 0.992 0.004 0.40% 0.988 0.997 0.980
Apr 9, 2024 0.985 0.009 0.92% 0.976 0.991 0.959
Apr 8, 2024 0.985 -0.005 -0.51% 0.990 0.997 0.980
Apr 5, 2024 0.994 -0.002 -0.20% 0.996 1.003 0.990
Apr 4, 2024 1.008 0.012 1.20% 0.996 1.014 0.996
Apr 3, 2024 1.007 0.007 0.70% 1.000 1.011 0.989
Apr 2, 2024 0.998 -0.015 -1.48% 1.013 1.013 0.997
Mar 28, 2024 1.007 0.000 0.00% 1.007 1.022 0.985
Mar 27, 2024 1.003 -0.012 -1.18% 1.015 1.029 0.991
Mar 26, 2024 1.012 -0.005 -0.49% 1.017 1.028 1.004
Mar 25, 2024 1.029 -0.002 -0.19% 1.031 1.046 1.028
Mar 22, 2024 1.030 -0.014 -1.34% 1.044 1.062 1.030
Mar 21, 2024 1.043 0.018 1.76% 1.025 1.045 1.023
Mar 20, 2024 1.027 -0.011 -1.06% 1.038 1.038 1.021
Mar 19, 2024 1.034 0.016 1.57% 1.018 1.040 1.002
Mar 18, 2024 1.027 -0.010 -0.96% 1.037 1.072 0.988

Pharming Group N.V. Events

Time (UTC) Country Event
Wednesday, May 8, 2024

Time (UTC)

10:59

Country

NL

Event

Q1 2024 Pharming Group NV Earnings Release
Q1 2024 Pharming Group NV Earnings Release

Forecast

-

Previous

-
Tuesday, May 21, 2024

Time (UTC)

12:30

Country

NL

Event

Pharming Group NV Annual Shareholders Meeting
Pharming Group NV Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

10:59

Country

NL

Event

Q2 2024 Pharming Group NV Earnings Release
Q2 2024 Pharming Group NV Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 205.622 198.871 212.174 178.487 142.697
Revenue 205.622 198.871 212.174 178.487 142.697
Cost of Revenue, Total 17.562 21.142 23.539 22.5509 23.4221
Gross Profit 188.06 177.729 188.635 155.936 119.275
Total Operating Expense 187.389 185.31 135.918 114.169 102.578
Selling/General/Admin. Expenses, Total 120.289 85.087 70.442 62.1213 49.3785
Research & Development 50.874 62.093 35.683 29.9566 30.4994
Other Operating Expenses, Total -2.281 -2.62 -1.829 -0.45936 -0.722304
Operating Income 18.233 13.561 76.256 64.3178 40.1195
Interest Income (Expense), Net Non-Operating -3.246 9.517 -28.418 -11.9814 -16.8274
Other, Net 0 -3.744 -3.04339 -22.3872
Net Income Before Taxes 14.987 23.078 44.094 49.293 0.904992
Net Income After Taxes 13.674 15.996 37.746 38.2219 26.3926
Net Income Before Extra. Items 13.674 15.996 37.746 38.2219 26.3926
Net Income 13.674 15.996 37.746 38.2219 26.3926
Income Available to Common Excl. Extra. Items 13.674 15.996 37.746 38.2219 26.3926
Income Available to Common Incl. Extra. Items 13.674 15.996 37.746 38.2219 26.3926
Diluted Net Income 13.674 15.996 37.746 38.2219 26.3926
Diluted Weighted Average Shares 707.141 701.152 682.737 673.52 653.528
Diluted EPS Excluding Extraordinary Items 0.01934 0.02281 0.05529 0.056749 0.040381
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS 0.00919 0.03807 0.05529 0.055862 0.043138
Depreciation / Amortization 8.811 9.169 8.083
Unusual Expense (Income) -7.866 10.439 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 66.661 54.897 42.541 54.621 54.238
Revenue 66.661 54.897 42.541 54.621 54.238
Cost of Revenue, Total 8.295 5.724 4.075 6.274 2.382
Gross Profit 58.366 49.173 38.466 48.347 51.856
Total Operating Expense 64.753 49.598 56.204 64.798 46.474
Selling/General/Admin. Expenses, Total 36.009 44.888 37.088 46.554 32.395
Research & Development 20.753 20.914 15.62 10.892 12.343
Other Operating Expenses, Total -0.304 -0.828 -0.579 1.078 -0.646
Operating Income 1.908 5.299 -13.663 -10.177 7.764
Interest Income (Expense), Net Non-Operating 1.399 -1.913 -3.011 -7.905 1.515
Net Income Before Taxes 3.307 3.386 -16.674 -18.082 9.279
Net Income After Taxes 3.464 1.319 -12.208 -14.63 9.101
Net Income Before Extra. Items 3.464 1.319 -12.208 -14.63 9.101
Net Income 3.464 1.319 -12.208 -14.63 9.101
Income Available to Common Excl. Extra. Items 3.464 1.319 -12.208 -14.63 9.101
Income Available to Common Incl. Extra. Items 3.464 1.319 -12.208 -14.63 9.101
Diluted Net Income 3.464 1.319 -12.208 -14.63 9.101
Diluted Weighted Average Shares 710.46 672.014 642.526 620.007 686.406
Diluted EPS Excluding Extraordinary Items 0.00488 0.00196 -0.019 -0.0236 0.01326
Diluted Normalized EPS 0.00488 -0.01845 -0.019 -0.0236 0.01326
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Other, Net
Unusual Expense (Income) -21.1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 277.5 249.444 263.212 119.435 121.905
Cash and Short Term Investments 207.342 191.924 205.159 74.348 84.8084
Cash & Equivalents 207.342 191.924 205.159 74.348 84.8084
Total Receivables, Net 25.331 27.591 31.884 28.864 16.8971
Accounts Receivable - Trade, Net 20.964 18.076 23.514 28.864 16.1938
Total Inventory 42.326 27.31 21.157 16.223 18.2846
Prepaid Expenses 2.288 2.392 4.017 1.91453
Total Assets 425.797 397.315 418.453 255.915 226.493
Property/Plant/Equipment, Total - Net 39.145 33.165 21.653 16.295 8.87251
Property/Plant/Equipment, Total - Gross 59.134 55.937 40.908 30.157 19.5582
Accumulated Depreciation, Total -19.989 -22.772 -19.255 -13.862 -10.6857
Intangibles, Net 75.121 83.834 94.083 79.403 55.3713
Other Long Term Assets, Total 24.3 22.222 32.387 34.605 40.3445
Total Current Liabilities 59.698 46.771 76.849 114.254 87.2245
Accounts Payable 8.753 7.599 46.874 7.01395
Accrued Expenses 45.712 34.84 0.616 2.26195
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.233 4.298 4.002 53.307 37.4859
Other Current Liabilities, Total 0 0 25.181 20.301 40.4627
Total Liabilities 221.159 204.399 235.018 138.527 161.284
Total Long Term Debt 161.461 157.463 157.957 4.893 39.5271
Long Term Debt 131.618 139.007 149.727 0 39.3539
Capital Lease Obligations 29.843 18.456 8.23 4.893 0.173184
Other Liabilities, Total 0 0.165 0.212 19.38 34.5322
Total Equity 204.638 192.916 183.435 117.388 65.209
Common Stock 7.509 7.429 7.312 7.226 6.56304
Additional Paid-In Capital 462.297 455.254 447.13 441.951 409.226
Retained Earnings (Accumulated Deficit) -265.168 -269.767 -271.007 -331.789 -350.58
Total Liabilities & Shareholders’ Equity 425.797 397.315 418.453 255.915 226.493
Total Common Shares Outstanding 656.348 648.749 638.822 631.323 621.501
Deferred Income Tax
Long Term Investments 9.731 8.65 7.118 6.177 0
Other Current Assets, Total 0.213 0.227 0.995 0
Payable/Accrued 0 0.034 0.176 40.646
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 291.737 278.573 266.056 277.5 252.048
Cash and Short Term Investments 197.565 192.373 184.78 207.342 188.703
Cash & Equivalents 54.653 87.347 184.78 207.342 188.703
Total Receivables, Net 40.521 33.158 32.931 27.619 28.828
Accounts Receivable - Trade, Net 40.521 33.158 32.931 27.619 28.828
Total Inventory 53.439 53.042 48.127 42.326 33.506
Other Current Assets, Total 0.212 0 0.218 0.213 1.011
Total Assets 436.467 429.805 422.996 425.797 382.323
Property/Plant/Equipment, Total - Net 37.482 39.346 40.772 39.145 27.782
Intangibles, Net 69.849 73.413 75.606 75.121 70.123
Long Term Investments 9.239 9.65 9.767 9.731 10.776
Other Long Term Assets, Total 28.16 28.823 30.795 24.3 21.594
Total Current Liabilities 68.058 64.952 59.003 59.698 46.694
Payable/Accrued 62.54 59.299 53.254 54.465 42.744
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.518 5.653 5.749 5.233 3.95
Other Current Liabilities, Total 0
Total Liabilities 226.525 229.433 223.653 221.159 182.069
Total Long Term Debt 158.467 164.481 164.65 161.461 135.232
Long Term Debt 129.733 134.183 133.576 131.618 120.005
Capital Lease Obligations 28.734 30.298 31.074 29.843 15.227
Other Liabilities, Total 0 0.143
Total Equity 209.942 200.372 199.343 204.638 200.254
Common Stock 7.65 7.54 7.518 7.509 7.482
Additional Paid-In Capital 475.983 464.363 463.222 462.297 459.45
Retained Earnings (Accumulated Deficit) -273.691 -271.531 -271.397 -265.168 -266.678
Total Liabilities & Shareholders’ Equity 436.467 429.805 422.996 425.797 382.323
Total Common Shares Outstanding 669.406 659.178 658.672 656.348 654.63
Cash 105.026
Short Term Investments 142.912
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 14.987 23.078 44.094 50.9457 41.4647
Cash From Operating Activities 22.458 37.842 83.626 72.5828 44.0666
Cash From Operating Activities 13.188 19.61 8.314 5.65021 7.15853
Non-Cash Items -4.18 0.062 37.077 19.6606 3.5689
Changes in Working Capital -1.537 -4.908 -5.859 -3.67367 -8.12551
Cash From Investing Activities 5.323 -21.305 -15.629 -27.522 -4.11351
Capital Expenditures -1.977 -16.716 -15.3 -24.7902 -2.72415
Other Investing Cash Flow Items, Total 7.3 -4.589 -0.329 -2.73179 -1.38936
Cash From Financing Activities -4.982 -27.947 60.686 -61.8248 -19.6027
Financing Cash Flow Items -3.952 -29.448 -25.513 -28.4333 -12.0742
Issuance (Retirement) of Stock, Net 2.281 4.718 2.791 3.03192 11.4554
Issuance (Retirement) of Debt, Net -3.311 -3.217 83.408 -36.4235 -18.9839
Foreign Exchange Effects -7.381 -1.825 2.128 1.47121 3.13888
Net Change in Cash 15.418 -13.235 130.811 -15.2928 23.4892
Cash Taxes Paid 1.235 0 2.658 5.56398 1.54652
Cash Interest Paid 3.952 4.448 2.142 9.18745 12.0742
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.674 14.987 33.069 23.79 4.233
Cash From Operating Activities -22.785 22.458 17.223 4.607 0.609
Cash From Operating Activities 2.306 13.188 6.216 4.263 2.19
Non-Cash Items 4.114 -4.18 -12.518 -12.973 -0.338
Cash Taxes Paid 0.44 1.235 4.975 3.422 0
Cash Interest Paid 2.013 3.952 3.999 2.052 2.1
Changes in Working Capital -12.531 -1.537 -9.544 -10.473 -5.476
Cash From Investing Activities -0.215 5.323 5.722 6.02 -0.374
Capital Expenditures -0.215 -1.977 -1.662 -1.558 -0.375
Other Investing Cash Flow Items, Total 7.3 7.384 7.578 0.001
Cash From Financing Activities -2.63 -4.982 -5.26 -3.34 -2.889
Financing Cash Flow Items -2.013 -3.952 -3.999 -2.052 -2.1
Issuance (Retirement) of Stock, Net 0.695 2.281 1.124 0.306 0.018
Issuance (Retirement) of Debt, Net -1.312 -3.311 -2.385 -1.594 -0.807
Foreign Exchange Effects 3.068 -7.381 -20.906 -9.247 0.404
Net Change in Cash -22.562 15.418 -3.221 -1.96 -2.25

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pharming Group Company profile

About Pharming Group N.V.

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pharming Group N.V. revenues decreased 10% to EUR167.7M. Net income decreased 59% to EUR13.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Research and development increase of 76% to EUR59.3M (expense), General and administrative increase of 48% to EUR31.2M (expense).

Equity composition

4/2010, Nominal value changed from EUR 0.5. 07/2012, Nominal value changed from EUR0.04. 3/2013, 1-for-10 reverse stock split (Factor: 0.1 ). 3/2013, Nominal value changed from EUR0.1 to EUR0.01. 11/2016, Rights Issue, 1 new share for every 7 shares held @ 0.205EUR, (Factor: 1.00751).

Industry: Pharmaceuticals (NEC)

Darwinweg 24
LEIDEN
ZUID-HOLLAND 2333 CR
NL

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

ETH/USD

3,115.84 Price
+1.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,767.40 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
+0.920% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,099.30 Price
+1.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading